drugset

drugset / Trial / NCT00165308

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

NCT00165308 ↗

Completed 29 enrolled Dana-Farber Cancer Institute AstraZeneca · collab Brigham and Women's Hospital · collab Massachusetts General Hospital · collab

NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.

Timeline

Start: 2001-04
Primary completion: 2004-03
Completion: 2009-06

Publications

Boucher AA, Blaes AH. Prophylactic mastectomy: a treatment alternative for Hodgkin survivors? Clin Breast Cancer. 2013 Oct;13(5):307-8. doi: 10.1016/j.clbc.2013.06.001. Epub 2013 Jul 26. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tamoxifen	Small molecule	20 mg	Oral

Indications